Larimar Corp (LRMR) Cash Funds per Share

Corporate emblem and logo of Larimar Therapeutics (LRMR)

Biotech development relies on the success of clinical trials, while the 1.49 level reflects current liquidity. Larimar Therapeutics (LRMR) is creating a treatment system for rare genetic brain pathologies via protein delivery. The cash per share figure confirms financial stability. Robotic platforms and AI automate drug discovery, which proves the technological superiority of Larimar Therapeutics (LRMR) on the chart.

Larimar Therapeutics Inc (LRMR): Cash Funds per Share from 07/04/2022 to 11/20/2026

Analytical breakdowns for Larimar Therapeutics

- market price and analyst price targets:
- cash position and cash flow details:
Summary company analysis:LRMR, Larimar Corp
Manufactured product of Larimar Therapeutics, Inc.

Larimar Therapeutics (LRMR) develops innovative drugs for the therapy of rare genetic pathologies, which requires significant capital expenditures for a diversified clinical trial pipeline. By analyzing the cash runway per share, an investor assesses the volume of net liquid assets per security, which determines the business's financial resilience and the company's horizon for autonomous operation without raising external capital.